US-based molecular diagnostic company Signal Genetics is set to merge with clinical-stage biopharmaceutical company miRagen Therapeutics, with the boards of directors of both companies having unanimously approved the merger that will create a clinical-stage biopharmaceutical company.
Mirage’s shareholders will hold roughly 96% of Signal’s outstanding common stock on a fully diluted basis and Signal’s name will be changed to MiRagen, Inc.
Go deeper with GlobalData
The merged company is expected to have a cash balance of $50m and will focus on developing proprietary micro RNA-targeted therapeutics.
Connemara Merger Sub 1 and Connemara Merger Sub 2, the subsidiaries of US-based biopharmaceutical company Celldex Therapeutics, have signed an agreement to acquire Kolltan Pharmaceuticals in a stock-for-stock transaction.
Following the acquisition, which is estimated to cost up to $235m, clinical-stage biopharmaceutical company Kolltan Pharmaceuticals will become a wholly owned subsidiary of Celldex Therapeutics.
See Also:
Celldex Therapeutics aims to expand its antibody and immuno-oncology portfolio through the acquisition.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
